This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Since my previous article, shares of Abbott Laboratories have returned 10% versus the 7% gains of the S&P 500 index. The healthcare company's sales and adjusted diluted EPS rose in the third quarter.

Is the company still worth a look if you're a long-term investor? Abbott Laboratories is one of the world's leading medical device makers. It routinely develops and markets newer products ...

Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

The Department of Justice announced an investigation into Abbott Laboratories' Michigan plant which was at center of a nationwide formula shortage in 2022. Abbott is recalling several of its ready ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also higher at its pharmaceutical unit, but fell at its diagnostics and ...

Investors happily greeted the latest news from Abbott Laboratories (NYSE: ABT) on Hump Day. After the storied healthcare company unveiled its third-quarter results, those folks traded its stock up ...

Abbott Laboratories ABT will release its quarterly earnings report on Wednesday, 2024-10-16. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Abbott ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing in Abbott Laboratories (NYSE: ABT). Abbott is a longtime leader in the ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...